ArticlePloS one2025
IQGAP1 participates in endothelial cell apoptosis and regulates atherosclerosis by targeting YAP.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial cell (EC) apoptosis plays a crucial role in the onset and progression of atherosclerosis (AS). IQGAP1 is highly expressed in various tissues and affects cell growth, development and death. However, the complete elucidation of the influence of IQGAP1 on EC apoptosis and AS remains unclear. This study endeavored to establish that IQGAP1 expression is augmented in the aortic wall of AS mice. Additionally, the present study demonstrated increased BAX and cleaved caspase-3 expression along with notably reduced BCL-2 expression within the aortic wall of mice with AS. After transfecting small interfering RNA of IQGAP1 (Si-IQGAP1) into normal or palmitic acid (PA)-treated human umbilical vein endothelial cells (HUVECs) cultured in vitro, the apoptotic rate decreased. Furthermore, western blot analysis demonstrated reduced expression pro-apoptotic proteins, namely BAX and cleaved caspase-3, accompanied by increased expression of the anti-apoptotic protein BCL-2. Simultaneously, the key protein of the Hippo signaling pathway, YAP, showed increased expression, whereas phosphorylated YAP expression decreased. However, subsequent to the overexpression of IQGAP1, the trajectory of the aforementioned parameters was reversed. In addition, the knockdown of YAP promoted the apoptosis rate in co-transfected Si-IQGAP1 and Si-YAP group. In conclusion, IQGAP1 potentially facilitates apoptosis in HUVECs, thereby contributing to AS initiation and progression. This mechanism may be partly attributed to the modulation of pivotal proteins, including YAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.